Cognitive Enhancement

Beta-Endorphin

A 31-amino acid endogenous opioid peptide produced in the pituitary and hypothalamus - the primary mediator of exercise-induced euphoria, stress analgesia, and immune modulation.

C₁₅₈H₂₅₁N₃₉O₄₆SHalf-life: ~20-30 minutes (plasma)Molar mass: 3464.10 g/mol

Community Rating

No ratings yet

Compound Profile

Beta-Endorphin

Key Data

FormulaC₁₅₈H₂₅₁N₃₉O₄₆S
Molar mass3464.1 g/mol
Half-life~20-30 minutes (plasma)
CategoryCognitive Enhancement

Research reference only

Research Focus

Most potent endogenous analgesic: mu-opioid receptor activation produces analgesia 18-33x more potent than morphine on a molar basis
Mediates the 'runner's high' - exercise-induced euphoria documented by PET imaging showing mu-opioid receptor occupancy
Regulates stress responses: released alongside ACTH under stress to modulate pain and mood

Preclinical data

⚠ Research & Educational Use Only. Beta-Endorphin is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.

Chemistry review: Ashish KumarWritten by the KnowYourPeptide Research TeamLast updated August 2026
Our editorial standards →
Key Takeaways
  • Most potent endogenous analgesic: mu-opioid receptor activation produces analgesia 18-33x more potent than morphine on a molar basis
  • Mediates the 'runner's high' - exercise-induced euphoria documented by PET imaging showing mu-opioid receptor occupancy
  • Regulates stress responses: released alongside ACTH under stress to modulate pain and mood
  • Beta-Endorphin is not FDA-approved for human use. It is a research chemical for scientific study only.

Research At a Glance

  • Most potent endogenous analgesic: mu-opioid receptor activation produces analgesia 18-33x more potent than morphine on a molar basis
  • Mediates the 'runner's high' - exercise-induced euphoria documented by PET imaging showing mu-opioid receptor occupancy
  • Regulates stress responses: released alongside ACTH under stress to modulate pain and mood
  • Immunomodulatory: activates natural killer cells, T lymphocytes, and monocytes via peripheral opioid receptors
Calculate Beta-Endorphin dose
Who researches this:Researchers studying the endogenous opioid system and mu-receptor pharmacologyThose investigating the neurochemistry of exercise, pain modulation, and rewardPeople researching endogenous analgesia mechanisms and their clinical implicationsScientists studying POMC-derived peptides and their interaction with the stress response
💡

In Plain English

Simple summary

Beta-endorphin is a 31-amino acid opioid peptide your brain produces naturally, cleaved from the same POMC precursor that makes alpha-MSH and ACTH. It's the most potent endogenous opioid peptide -- significantly more potent than enkephalins -- and it binds primarily to mu-opioid receptors, the same receptors targeted by morphine, oxycodone, and heroin. Your brain releases it during exercise (it's the actual molecule behind 'runner's high,' not endorphins generally), orgasm, certain foods, laughing, and pain. It acts as both a painkiller and a mood elevator. Unlike synthetic opioids, beta-endorphin doesn't cause respiratory depression at physiological doses because of how it interacts with the biased agonism of mu receptors endogenously.

  • Most potent endogenous analgesic: mu-opioid receptor activation produces analgesia 18-33x more potent than morphine on a molar basis
  • Mediates the 'runner's high' - exercise-induced euphoria documented by PET imaging showing mu-opioid receptor occupancy
  • Regulates stress responses: released alongside ACTH under stress to modulate pain and mood

The full scientific detail, mechanisms, citations, and dosing data, follows below.

What is Beta-Endorphin?

Tap any underlined term for an instant definition.

Beta-endorphin is a 31-amino acid opioid peptide derived by post-translational processing of the precursor protein proopiomelanocortin (POMC) in the anterior and intermediate lobes of the pituitary gland, and in neurons of the hypothalamic arcuate nucleus that project throughout the brain and spinal cord. The name derives from " morphine" - coined when the ligands for opioid receptors were first identified in 1975, in a discovery that explained why plant-derived opiates (morphine, codeine) were pharmacologically active in mammalian tissues - they were mimicking molecules the body itself produces.

Beta-endorphin is one of three families of opioid peptides (the others being the enkephalins and dynorphins) and is the primary agonist at the mu-opioid receptor (MOR). On a molar basis, beta-endorphin is approximately 18-33x more potent than morphine at MOR, making it the most potent analgesic molecule produced endogenously. The high potency and selectivity of beta-endorphin for MOR, combined with its hypothalamic and pituitary origins, position it as a major neuromodulator of pain, stress, mood, and reproductive physiology.

The co-regulation of beta-endorphin and ACTH (adrenocorticotropic hormone) from the same POMC precursor ensures their simultaneous release during stress. When the hypothalamo-pituitary-adrenal (HPA) axis is activated - by pain, psychological stress, exercise, or illness - CRH stimulates corticotroph cells to cleave POMC into ACTH (which drives cortisol release) and beta-endorphin (which produces analgesia and mood elevation). This coordinated release makes biological sense: the capacity to tolerate pain is enhanced precisely when the animal is under attack or exertion.

The "runner's high" represents the most socially prominent manifestation of beta-endorphin biology. The phenomenon - characterised by euphoria, reduced pain sensitivity, and emotional well-being during and after sustained aerobic exercise - has been debated mechanistically for decades. The popular attribution to endorphins was long based on indirect evidence (naloxone blockade of exercise analgesia) and was complicated by the fact that plasma beta-endorphin levels rise during exercise but the peptide crosses the blood-brain barrier poorly. In 2008, Boecker and colleagues used PET imaging with a mu-opioid receptor ligand to directly demonstrate increased opioid receptor occupancy in the frontal and limbic regions of marathon runners' brains after a long run, with the degree of opioid binding correlating with subjective euphoria ratings. This provided the first direct evidence that exercise-induced endorphin release in the brain mediates the affective components of the runner's high.

The immune-modulatory properties of beta-endorphin are mediated through opioid receptors expressed on natural killer cells, T and B lymphocytes, macrophages, and dendritic cells. Beta-endorphin stimulates natural killer cell cytotoxicity, enhances T-cell proliferation, and modulates cytokine production. These immune effects appear to provide a link between psychological states and immune function - explaining, for example, why acupuncture (which elevates brain endorphin levels, as documented by PET) may have immune-modulatory effects and why psychological stress (which acutely elevates then depletes endorphins) affects immune function.

The opioid system's role in social bonding has emerged as an important area of neuroscience research. The "social pain" hypothesis - supported by imaging and pharmacological studies - proposes that social exclusion and rejection activate some of the same neural circuits as physical pain, and that opioids buffer against social distress. Studies using naltrexone (opioid receptor blocker) have shown that opioid blockade reduces social warmth and increases loneliness in healthy humans. Conversely, positive social interactions, laughter, and physical touch elevate endorphin levels as measured by PET opioid receptor occupancy studies, suggesting the endorphin system mediates the reinforcing and stress-buffering qualities of social affiliation.

By the Numbers

18–33x more potent than morphine
Beta-endorphin's binding affinity for mu-opioid receptors is significantly higher than morphine in receptor binding assays
Runner's high confirmed
A 2021 Neuron study using mu-receptor PET imaging showed endorphin release specifically correlated with runner's high feelings during running
POMC-derived
Cleaved from pro-opiomelanocortin alongside alpha-MSH -- produced in the pituitary, hypothalamus, and immune cells

Key Research Benefits

Documented effects observed in preclinical and clinical studies on Beta-Endorphin. See all Cognitive Enhancement peptides for comparison.

Most potent endogenous analgesic: mu-opioid receptor activation produces analgesia 18-33x more potent than morphine on a molar basis
Mediates the 'runner's high' - exercise-induced euphoria documented by PET imaging showing mu-opioid receptor occupancy
Regulates stress responses: released alongside ACTH under stress to modulate pain and mood
Immunomodulatory: activates natural killer cells, T lymphocytes, and monocytes via peripheral opioid receptors
Hypothalamic regulation: modulates GnRH, GHRH, and CRH release to coordinate the stress response
Anti-depressant properties: endorphin deficiency linked to depression; mu-opioid agonism produces euphoria
Reduces systemic inflammation through peripheral opioid receptors on immune cells
Enhances memory consolidation via mu-opioid receptors in the hippocampus and basolateral amygdala

Side Effects & Risks

Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →

Dosing Data from the Literature

Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.

Research Dosing Protocol

Beta-endorphin is used primarily as a research tool rather than a therapeutic agent:

IV/ICV research administration: - Pain and analgesia research: 0.1-10 nmol intracerebroventricularly in rodent models - Immune function research: 10-100 ng/mL in cell culture assays - Neuroendocrine research: 0.01-1 nmol ICV for GnRH/ modulation studies

Induction of beta-endorphin release (research): - High-intensity exercise (>70% VO2max) for 30+ minutes reliably elevates plasma beta-endorphin 2-5 fold - Electrical acupuncture stimulation produces measurable CNS beta-endorphin release (PET-documented) - Social laughter and positive social interaction - documented to elevate beta-endorphin via PET

Enter your vial size and target dose to get the exact injection volume.

Administration in Research Settings

Standard reconstitution and administration methodology for laboratory research use.

Research applications only - not intended for direct clinical administration. Used in: - Receptor binding assays: radiolabelled ([125I]-beta-endorphin) for opioid receptor characterisation - Electrophysiology: bath application to neuronal preparations to study opioid-sensitive currents - ICV delivery in rodents: via stereotaxically implanted cannula for dose-response studies - Cell biology: added to culture media for immune cell activation assays

What the research doesn't show

Exogenous beta-endorphin administration is not a practical research tool -- it doesn't cross the blood-brain barrier and degrades rapidly. The 'runner's high' research is genuine, but the mechanism is more complex than 'endorphins make you feel good': the timing, receptor, and brain region involved all matter. Peripheral beta-endorphin from immune cells has immune-regulatory effects separate from its CNS opioid actions.

Research Video

Medical Expert Videos

Physicians, researchers, and pharmacologists explain Beta-Endorphin, covering mechanisms of action, clinical context, and study findings.

YouTube, Beta-Endorphin · doctors & researchersOpen in YouTube

Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.

📋

The Bottom Line

Beta-Endorphin has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: most potent endogenous analgesic: mu-opioid receptor activation produces analgesia 18-33x more potent than morphine on a molar basis.

The most commonly reported side effect in research subjects is tolerance development with chronic exogenous administration - as with all opioid receptor agonists. It is a research chemical, not approved for human use.

Research chemicalNot for human useEducational purposes only

Frequently Asked Questions

Explore Further

Quick Reference

Half-Life
~20-30 minutes (plasma)
Molar Mass
3464.10 g/mol
Formula
C₁₅₈H₂₅₁N₃₉O₄₆S
Legal Status
Research chemical. Not approved for clinical administration. Prescription opioids targeting the same mu-opioid receptors are controlled substances; the endogenous ligand itself is unscheduled.
Storage
Lyophilised: -20°C dessicated, protect from light. Solutions in PBS or acetic acid (0.1 M): -80°C for long-term storage, -20°C for up to 6 months. Avoid repeated freeze-thaw.

How It Compares

Enkephalins and dynorphins are the other major endogenous opioid peptide families -- they also bind mu receptors but with different affinity profiles and receptor selectivity. Synthetic opioids (morphine, oxycodone) mimic beta-endorphin's receptor binding but lack the endogenous signaling context that prevents respiratory depression. Researchers studying non-addictive opioid analogues often study how beta-endorphin's biased agonism differs from synthetic opioids to inform drug design.

Compare Beta-Endorphin side-by-side

Research Use Only

This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.

AI Peptide Advisor

online · Claude + Gemini
ask your question...